Navigation Links
Synergy Pharmaceuticals to Present Scientific Posters at the Upcoming Gastroenterology Society Meetings in the U.S. and Europe
Date:7/31/2012

inflammation.

Forward-Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "planned," "believe," "forecast," "estimated," "expected," and "intend," among others. These forward-looking statements are based on Synergy's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Investors should read the risk factors set forth in Synergy's Form 10-K for the year ended December 31, 2011 and other periodic reports filed with the Securities and Exchange Commission.  While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the d
'/>"/>

SOURCE Synergy Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent
2. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
3. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
4. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
5. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
6. Icahn Issues Statement Regarding Amylin Pharmaceuticals
7. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
8. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
9. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
10. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
11. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014  Seventy-one percent of Americans ... OxyContin is a serious public health and safety issue in ... from a survey released today by Repass & Partners, a ... "Americans understand the severity of the prescription medication ... progress with this very serious health situation facing our country," ...
(Date:8/21/2014)... FAIRFAX, Va. , Aug. 21, 2014 /PRNewswire/ ... real-time quality and Manufacturing Intelligence , today ... Intelligence Conference. The event will be held Oct. ... Mile, and is designed to showcase the necessity ... use of metrics and Manufacturing Intelligence to gain ...
(Date:8/21/2014)... -- Professional Compounding Centers of America (PCCA) will ... three best scientific presentations at the sixth ... Formulating Better Medicines for Children  conference, held ... Greece , includes dozens of poster-style scientific ... three winners will be selected by a panel ...
Breaking Medicine Technology:Consumers Desperate For Measures To Curb Prescription Drug Abuse 2Consumers Desperate For Measures To Curb Prescription Drug Abuse 3InfinityQS to Host Manufacturing Intelligence Conference in Chicago 2Professional Compounding Centers of America will award top poster-session winners at European Paediatric Formulation Initiative in Athens 2
... 22, 2011 Orexigen Therapeutics, Inc. (Nasdaq: OREX ... 5,646,173 units.  Each unit consisted of one share of common ... stock, at a price to the public of $1.45 per ... each share of common stock, which together comprised the purchase ...
...  Provenance Biopharmaceuticals Corp. ("Provenance") announced today the closing ... Enterprises, LLC for the continued development of anti-cancer ... class of molecules called immunocytokines that are being ... cancer.  Immunocytokines, combine the immune stimulating features of ...
Cached Medicine Technology:Orexigen® Therapeutics Completes Public Offering of Common Stock and Warrants to Purchase Common Stock 2Provenance Biopharmaceuticals Corp. Announces $8M Financing Arrangement 2
(Date:8/21/2014)... August 11: – Robin William’s suicide ... by hanging, likely due to long-term depression. ... BioAcoustic Vocal Profiling investigator, appeared on the Joyce Riley ... death; hoping to help people understand why he chose ... suicide were proposed in terms of BioAcoustic Biology: Using ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 AVEC ... to announce the addition of Kerry Gillespie as ... of healthcare management experience, Gillespie brings an extremely ... multiple executive management positions with prominent industry leading ... served as President of Triad Isotopes, Inc. a ...
(Date:8/21/2014)... Las Vegas, NV (PRWEB) August 21, 2014 ... - the Association for Packaging and Processing Technologies. ... packaging. It’s the view into a whole new ... thousands of engaged attendees, interactive education, and the ... pharmaceutical lifecycle solutions from exhibitors. This year at ...
(Date:8/21/2014)... is an internationally well-known supplier and leader in the ... collection of elegant bamboo floorings . These new ... for high quality floorings for their own houses. Now, ... to 29 percent off). Before the end of August, ... The company’s bamboo flooring products are made using unique, ...
(Date:8/21/2014)... 2014 An increasing amount of complaints ... their federal tax payment is being returned by their ... from the IRS, “tax@irs.gov”, it’s actually a phishing tactic ... financial information. , While similar scams have been going ... phishing activity is occurring right now. , First, ...
Breaking Medicine News(10 mins):Health News:Robin Williams: What he could not bear to face 2Health News:Robin Williams: What he could not bear to face 3Health News:Kerry Gillespie Appointed as Chief Executive Officer of AVEC Health Solutions 2Health News:Absolute I&D Provides Discounted Labor for Pack Expo Chicago 2Health News:Buy Elegant Bamboo Floorings from Internationally Well-known Supplier BambooIndustry.com 2Health News:Beware Of Phony “Tax Payment Rejected” IRS Emails 2
... , , WASHINGTON, Dec. 1 The following ... , Chairman Kerry, Ranking Member Lugar, and Members of the ... Obama to serve as Administrator of the United States Agency ... to lead the Agency. , Secretary of State Clinton ...
... , FORT LAUDERDALE, Fla., Dec. 1 OrbusNeich today ... the Combo Bio-engineered Sirolimus Eluting Stent (Combo Stent). , A prospective, randomized, ... valuation of an ablu M inal sirolimus coat ED ... will enroll 180 patients at up to 20 sites in Asia, Australia, ...
... believe that happiness declines with age are more likely to ... misguided negative view of the aging process may act as ... the most of the present in anticipation of ,miserable, old ... and Dr. Maria Lohan from Queen,s University Belfast, Northern Ireland, ...
... Method improves diagnosis of benign versus cancerous lesions, researchers ... used with ultrasound, elastography helps distinguish between cancerous and ... have found. , About 80 percent of breast lesions ... to the American Cancer Society. , "There,s a lot ...
... ... but gains at risk. , ... (Vocus) December 1, 2009 -- WHAT: Measles Initiative partners -- the American ... the World Health Organization – will announce the latest global health achievement during a press ...
... ... their greatest asset is the ability to earn an income. It is this ... only pay today,s mortgage but also to plan and save for tomorrow,s college ... , only 10 percent of adults age 21 and over have taken measures ...
Cached Medicine News:Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 2Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 3Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 4Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 5Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 6Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 7Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 8Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 9Health News:OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent 2Health News:OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent 3Health News:OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent 4Health News:Binge drinking youths find getting old a drag 2Health News:Ultrasound With Elastography May Cut Down on Biopsies 2Health News:**MEDIA ADVISORY** Measles Initiative to Announce Major Achievement in Public Health 2Health News:Northwestern Mutual Survey Reveals That Most Americans Are Putting Their Income at Risk 2Health News:Northwestern Mutual Survey Reveals That Most Americans Are Putting Their Income at Risk 3
EchoScan US-2500 is available in a single configuration or in combination with the A scan for maximum cost efficiency....
EchoScan US-3300 takes accurate axial length and corneal thickness measurements in either automatic or manual modes. It is available in a single configuration or in combination with the A scan for ma...
PremierEdge Stab Knives - 45....
... The Answer to Micro-Incision ... Technology With its unique ... microsurgical knife is ideal for ... creates reproducible incisions that allow ...
Medicine Products: